Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1685-1685
Author(s):  
Kenichiro Yata ◽  
Masahiro Abe ◽  
Asuka Oda ◽  
Hiroe Amou ◽  
Masahiro Hiasa ◽  
...  

Abstract Multiple myeloma (MM) remains incurable by conventional chemotherapies, leading to the idea to develop various forms of immunotherapies. γδ T cells are important effectors in the first-line defense against infections and tumors, and play a critical role in host defense and tumor surveillance. Aminobisphosphonates, a potent anti-resorptive agent, can effectively expand γδ T cells in vitro from peripheral blood mononuclear cells (PBMC) in combination with IL-2 in human; thus expanded γδ T cells have been demonstrated to exert potent anti-MM effects and draws considerable attention as a novel immunotherapeutic maneuver. However, in contrast to their in vitro anti-MM effects, their efficacy against MM cell growth in the bone marrow appears to be limited in patients with MM, although their clinical application is underway in MM. MM cells expands in a manner dependent on bone marrow microenvironment, in which stromal cells with defective osteoblast differentiation along with osteoclasts create a microenvironment suitable for MM cell growth and survival (a MM niche) to protect MM cells from various apoptotic insults. Because the effects of MM bone marrow microenvironment on γδ T cell activity is largely unknown, the present study was undertaken to clarify the roles of microenvironmental cells in MM bone marrow in cytotoxic activity of γδ T cells against MM cells. γδ T cells were substantially expanded (30- to 100-fold increase) when PBMC were stimulated with zoledronic acid and IL-2 for 1–2 weeks. When the γδ T cells were added exogenously to co-cultures of PBMC–derived OCs and MM cell lines (RPMI8226 and U266), γδ T cells adhered to OCs as well as MM cells and almost completely destroyed both of them, suggesting the susceptibility of OCs and MM cells to γδ T cells. Because such γδ T cell-mediated cytolysis is contact-dependent, we next explored the adhesion-mediated mechanisms. We found strong surface expression of DNAX accessory molecule-1 (DNAM-1; CD226) along with LFA-1 on γδ T cells, both of which are known as an adhesion molecule with signal transduction, and act as co-stimulatory molecules in cytotoxic T cells and NK cells. Blockade of either DNAM-1 or LFA-1 substantially reduced cytolysis of OCs as well as MM cells by γδ T cells, demonstrating their critical role as co-stimulatory molecules in γδ T cells. In contrast, the cytotoxic activity of γδ T cells against MM cells was potently attenuated in the presence of bone marrow stromal cells. Pretreatment of γδ T cells with stromal cells down-regulated interferon-γ production along with a decrease in DNAM-1 expression by γδ T cells. These results suggest that bone marrow stromal cells may be responsible for attenuation of anti-MM effects by γδT cells in vivo through directly blunting γδ T cell activity in addition to protection of MM cells from apoptosis. We and others have recently demonstrated that terminally differentiated osteblasts derived from stromal cells induce MM cell apoptosis. In contrast to stromal cells, terminally differentiated osteblasts allowed MM cell eradication by γδ T cells. Therefore, induction of terminally differentiation of osteblasts from stromal cells not only ameliorates bone lesions but also may disrupt a MM niche to confer susceptibility to γδ T cells in MM cells, which is hampered by bone marrow stromal cells.

Blood ◽  
2002 ◽  
Vol 99 (10) ◽  
pp. 3838-3843 ◽  
Author(s):  
Massimo Di Nicola ◽  
Carmelo Carlo-Stella ◽  
Michele Magni ◽  
Marco Milanesi ◽  
Paolo D. Longoni ◽  
...  

CD2+ T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs) or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic dendritic cells (DCs) or peripheral blood lymphocytes (PBLs). When autologous or allogeneic BMSCs were added back to T cells stimulated by DCs or PBLs, a significant and dose-dependent reduction of T-cell proliferation, ranging from 60% ± 5% to 98% ± 1%, was evident. Similarly, addition of BMSCs to T cells stimulated by polyclonal activators resulted in a 65% ± 5% (P = .0001) suppression of proliferation. BMSC- induced T-cell suppression was still evident when BMSCs were added in culture as late as 5 days after starting of MLRs. BMSC-inhibited T lymphocytes were not apoptotic and efficiently proliferated on restimulation. BMSCs significantly suppressed both CD4+ and CD8+ T cells (65% ± 5%, [P = .0005] and 75% ± 15% [P = .0005], respectively). Transwell experiments, in which cell-cell contact between BMSCs and effector cells was prevented, resulted in a significant inhibition of T-lymphocyte proliferation, suggesting that soluble factors were involved in this phenomenon. By using neutralizing monoclonal antibodies, transforming growth factor β1 and hepatocyte growth factor were identified as the mediators of BMSC effects. In conclusion, our data demonstrate that (1) autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, (2) this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and (3) T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.


Blood ◽  
2000 ◽  
Vol 95 (12) ◽  
pp. 3758-3764 ◽  
Author(s):  
Anne Solanilla ◽  
Julie Déchanet ◽  
Abdel El Andaloussi ◽  
Moryse Dupouy ◽  
François Godard ◽  
...  

Abstract CD40 ligand (CD40L)/CD40 interactions play a central role in T-cell–dependent B-cell activation as previously shown by in vitro studies, the phenotype of CD40L knockout mice and the defective expression of CD40L in patients who have X-linked immunodeficiency with hyper-IgM. The distribution of CD40 in cells other than of myeloid and lymphoid lineages has suggested additional functions for this receptor/ligand couple. Here we show that CD40L stimulates myelopoiesis with a noticeable effect on megakaryocytopoiesis in cocultures of hematopoietic progenitor cells and bone marrow stromal cells. These results suggest a mechanism by which T-cell or platelet-associated or soluble CD40L may regulate myelopoiesis.


2013 ◽  
Vol 19 (6) ◽  
pp. 1467-1475 ◽  
Author(s):  
Teun Guichelaar ◽  
Maarten E. Emmelot ◽  
Henk Rozemuller ◽  
Bianka Martini ◽  
Richard W.J. Groen ◽  
...  

2013 ◽  
Vol 210 (6) ◽  
pp. 1125-1135 ◽  
Author(s):  
Eric Tran ◽  
Dhanalakshmi Chinnasamy ◽  
Zhiya Yu ◽  
Richard A. Morgan ◽  
Chyi-Chia Richard Lee ◽  
...  

Fibroblast activation protein (FAP) is a candidate universal target antigen because it has been reported to be selectively expressed in nearly all solid tumors by a subset of immunosuppressive tumor stromal fibroblasts. We verified that 18/18 human tumors of various histologies contained pronounced stromal elements staining strongly for FAP, and hypothesized that targeting tumor stroma with FAP-reactive T cells would inhibit tumor growth in cancer-bearing hosts. T cells genetically engineered with FAP-reactive chimeric antigen receptors (CARs) specifically degranulated and produced effector cytokines upon stimulation with FAP or FAP-expressing cell lines. However, adoptive transfer of FAP-reactive T cells into mice bearing a variety of subcutaneous tumors mediated limited antitumor effects and induced significant cachexia and lethal bone toxicities in two mouse strains. We found that FAP was robustly expressed on PDGFR-α+, Sca-1+ multipotent bone marrow stromal cells (BMSCs) in mice, as well as on well-characterized, clinical-grade multipotent human BMSCs. Accordingly, both mouse and human multipotent BMSCs were recognized by FAP-reactive T cells. The lethal bone toxicity and cachexia observed after cell-based immunotherapy targeting FAP cautions against its use as a universal target. Moreover, the expression of FAP by multipotent BMSCs may point toward the cellular origins of tumor stromal fibroblasts.


Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4441
Author(s):  
Takeshi Harada ◽  
Masahiro Hiasa ◽  
Jumpei Teramachi ◽  
Masahiro Abe

Multiple myeloma (MM) has a propensity to develop preferentially in bone and form bone-destructive lesions. MM cells enhance osteoclastogenesis and bone resorption through activation of the RANKL–NF-κB signaling pathway while suppressing bone formation by inhibiting osteoblastogenesis from bone marrow stromal cells (BMSCs) by factors elaborated in the bone marrow and bone in MM, including the soluble Wnt inhibitors DKK-1 and sclerostin, activin A, and TGF-β, resulting in systemic bone destruction with loss of bone. Osteocytes have been drawn attention as multifunctional regulators in bone metabolism. MM cells induce apoptosis in osteocytes to trigger the production of factors, including RANKL, sclerostin, and DKK-1, to further exacerbate bone destruction. Bone lesions developed in MM, in turn, provide microenvironments suited for MM cell growth/survival, including niches to foster MM cells and their precursors. Thus, MM cells alter the microenvironments through bone destruction in the bone where they reside, which in turn potentiates tumor growth and survival, thereby generating a vicious loop between tumor progression and bone destruction. The serine/threonine kinases PIM2 and TAK1, an upstream mediator of PIM2, are overexpressed in bone marrow stromal cells and osteoclasts as well in MM cells in bone lesions. Upregulation of the TAK1–PIM2 pathway plays a critical role in tumor expansion and bone destruction, posing the TAK1–PIM2 pathway as a pivotal therapeutic target in MM.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5771-5771
Author(s):  
Giulia Barbarito ◽  
Irma Airoldi ◽  
Alessia Zorzoli ◽  
Alice Bertaina ◽  
Andrea Petretto ◽  
...  

Abstract A new method of graft manipulation based on physical removal of αβ+ T cells and CD19+ B cells, leaving mature NK cells and γδ T cells in the graft, has been recently developed for HLA-haploidentical HSCT. We demonstrated that γδ T cells collected from transplanted patients are endowed with capacity of killing leukemia cells after ex vivo treatment with zoledronic acid (ZOL). Thus, we hypothesized that infusion of ZOL in patients receiving this type of graft, may boost γδ T cell cytotoxic activity against leukemia cells. Thirty-three patients were treated with ZOL every 28 days at least twice. γδ T cells before and after ZOL treatments were studied till at least 7 months after HSCT by high-resolution mass spectrometry, flow-cytometry, and degranulation assay. Proteomic analysis of γd T cells purified from patients showed that, starting from the first infusion, ZOL caused up-regulation of proteins involved in activation processes and immune response, paralleled by down-regulation of proteins involved in proliferation. These findings are consistent with an induction of Vδ2 cell differentiation, paralleled by increased cytotoxicity of both Vδ1 and Vδ2 cells against primary leukemia blasts. Furthermore, a proteomic signature was identified for each individual ZOL treatment. Patients given 3 or more ZOL infusions had a better probability of survival in comparison to those given 1 or 2 treatments. In conclusion,ZOL influences Vδ2 cell activity, determines a specific proteomic signature and enhances anti-leukemia activity, this potentially resulting into an increased anti-tumor effect. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Preethi Balasubramanian ◽  
Rainer Detsch ◽  
Leticia Esteban-Tejeda ◽  
Alina Grünewald ◽  
José S. Moya ◽  
...  

AbstractThis study evaluated the influence of ionic dissolution products of a novel Ca-enriched silicate bioactive glass compared to commercial available hydroxyapaptite samples (Endobonr) on cell activity and vascular endothelial growth factor (VEGF) release in vitro. Bone marrow stromal cells (ST-2) were cultivated with the supernatant of granules of different sizes and at different concentrations (0-1 wt/vol % of granules) for 48 h. In addition to in vitro studies, Ca-ion release from all as cell morphology observation revealed no cytotoxic effect of the released products from all tested materials. It was found that supernatants from granules in concentrations of 1 wt/vol %enhanced the VEGF release from ST2 cells, which is important as a marker of the vascularisation ability of the glass during the bone healing process.


Sign in / Sign up

Export Citation Format

Share Document